Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2020-06-19
2022-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy
NCT03359642
Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.
NCT05835973
Platelet Indices in Inflammatory Bowel Diseases
NCT07320443
Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe
NCT07292454
Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease
NCT01891214
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diseases activity will be assessed by HBI (Crohn's disease) or partial Mayo score (Ulcerative Colitis) associated with fecal calprotectin and/or CRP and/or inflammatory/ulcerative lesions.
Periodontal diseases (periodontitis and gingivitis) will be diagnosed according to the international classification of periodontal diseases (Chicago 2017) and based on the decision-making algorithms by Tonetti and Sanz. A periodontal screening, socio-demographic data and clinical data will be collected. Then, oral mucosa dermatological manifestations relative to IBD, treatment need (ICDAS) and quality of life related to oral health (GOHAI) will be evaluated. These data will be collected by a periodontist.
The principal hypothesis of this study is that the prevalence of periodontal diseases could be increased in patient presenting an active IBD.
The primary objective is to evaluate if patients presenting active IBD present more stage III and IV periodontal diseases than non-active IBD ones.
The second objectives are :
* to compare periodontal diseases, gingivitis and oral mucosa dermatological manifestations rates according to the diseases activity, the IBD type and the treatment used to treat IBD,
* to compare oral treatment need according to the activity and the type of IBD,
* to compare quality of life related to oral health according to the activity and the type of IBD
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active IBD
Active Inflammatory Bowel Diseases defined as :
For Crohn's disease :
* Harvey Bradshaw Index ≥ 4
* Associated with fecal calprotectin rate \> 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis
* Partial Mayo score ≥ 2
* Associated with fecal calprotectin rate \> 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months
Periodontal screening
Periodontal data collection (PPD, REC, CAL)
Non-active IBD
Non-active Inflammatory Bowel Diseases
Periodontal screening
Periodontal data collection (PPD, REC, CAL)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Periodontal screening
Periodontal data collection (PPD, REC, CAL)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* consulting Gastroenterology departments in the university hospital of Reims or Amiens-Picardie for the management of Crohn's disease or Ulcerative colitis
* signed informed consent form
* affiliated to the French Social Security system
Exclusion Criteria
* a medical history likely to compromise protocol (psychiatric disorders, other inflammatory diseases, antibiotics, NSAIDs within the last 3 months)
* Diabetes
* Inflammatory rheumatism
* Cancer or radiotherapy up to5 years before inclusion
* X-ray therapy in the area of interest
* Pregnancy or Breastfeeding
* Eating disorders
* Patients under legal protection, trusteeship or guardianship
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Reims
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PO20062*
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.